# Study Evaluating SKI-606 in Subject With Solid Tumors

> **NCT01001936** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 28 (actual)

## Conditions studied

- Tumors

## Interventions

- **DRUG:** SKI-606

## Key facts

- **NCT ID:** NCT01001936
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2009-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01001936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01001936, "Study Evaluating SKI-606 in Subject With Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01001936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*